Enteric-coated formulation of Myfortic reduces GI disorders

In a new multicenter study, kidney transplant physicians reported a significant reduction in the incidence and symptom severity of gastrointestinal (GI) complications after conversion from MMF to enteric-coated Myfortic (mycophenolic acid), Novartis’s immunosuppressive agent for transplanted patients.

Results of the local PROGIS (Patient-reported Outcomes in Renal Transplant Patients with an...